摘要
目的观察信必可都保与顺尔宁联合治疗咳嗽变异性哮喘的临床疗效和安全性。方法将68例咳嗽变异性哮喘门诊病例随机分成两组,试验组使用信必可都保联合顺尔宁,对照组单用信必可都保,各治疗12周,在治疗前后观察晨间呼气峰流速、日、夜间咳嗽症状积分以及诱导痰中炎性细胞的变化。结果两组治疗后晨间呼气峰流速、日、夜间咳嗽症状积分均显著改善,诱导痰中相关炎性细胞数较治疗前明显减少,且试验组疗效优于对照组,治疗期间两组患者血压、心率、血糖、肝功、心电图均无明显改变,两组患者不良事件发生率低,均为5.9%。结论应用信必可都保联合顺尔宁治疗咳嗽变异性哮喘疗效相加,对单用信必可都保仍不能有效控制咳嗽的患者可以加用顺尔宁。
Objective To observe the clinical effect and safety of symbicort combine Singulair on patients with cough variant asthma.Methods Totally 68 outpatients with cough variant asthma were randomly divided into two groups： experimental group treated with symbicort combine Singulair and control group treated with Symbicort for 12 weeks respectively.The morning peak expiratory flow,day and night time cough symptom scores and inflammatory cell in the induced sputum before and after treatment were observed in the two groups.Results Both the morning peak expiratory flow and day and night time cough symptom scores after treatment improved significantly in the two groups.The inflammatory cells in the induced sputum were also obviously decreased than that of pretherapy and experimental group obviously outweigh control group.The blood pressure,heart rate,blood glucose,liver function and electrocardiogram showed no significant difference during treatments in the two groups.The incidence of adverse events were 5.9%,obviously decreased in the two groups.Conclusions The therapeutic effect of Symbicort combine Singulair on cough variant asthma were doubled,the patients who single-use Symbicort can not achieve effective control cough may use Singulair.
出处
《医药论坛杂志》
2011年第8期82-84,共3页
Journal of Medical Forum
